There is no "best" outcome or "gold standard" in the assessment of inhaled drug delivery. All levels of inquiry are important in development of drug formulations and delivery devices, and culminate in optimal therapy for the patient. Some advantages and disadvantages of each approach are summarized in Table 3. Each level forms a framework for the next step in the process, with in vitro leading to in vivo, followed by clinical trials. For optimal design, predictions and measurements of inhaled drug delivery should be done prior to large, expensive clinical trials. Bench testing with in vitro models is essential to document the performance of the delivery device/drug combination, whereas in vivo studies examine the behavior of the aerosol in human subjects. Both scintigraphy and pharmacokinetic/pharmacodynamic studies can add insights into the relationship between drug delivery and clinical efficacy and toxicity.
BatesDV, FishBR. Deposition and retention models for internal dosimetry of the human respiratory tract. Task Group on Lung Dynamics. Health Phys1966;12:173–208.
2.
PhelanRF, CuddihyFG, FisherGL, MossOR, SchlesingerRB, SwiftDL, YehH-C. Main features of the proposed NCRP respiratory tract model. Rad Prot Dos1991;38:179–184.
3.
BairWJ. Overview of ICRP respiratory tract model. Rad Prot Dos1991;38:147–152.
4.
PhalenRF, OldhamMJ, KleinmanMT, CrockerTT. Tracheobronchial deposition predictions for infants, children and adolescents. In: DodgsonJ, McCallumRI, BaileyMR, FisherDR, editors. Inhaled particles VI. Oxford: Pergamon Press; 1988: 11–21.
5.
HofmannW.Modeling techniques for inhaled particle deposition: the state of the art (review). J Aerosol Med1996;9(3):369–388.
6.
HeyderJ, GebhartJ, RudolfG, SchillerCF, StahlhofenW.Deposition of particles in the human respiratory tract in the size range 0.0005-15 µm. J Aerosol Sci1986;17:811–825.
7.
MartonenTB, KatzIM. Deposition patterns of aerosolized drugs within human lungs: effects of ventilatory parameters. Pharm Res1993;10(6):871–878.
8.
FerronGA, OberdörsterG, HennebergR.Estimation of the deposition of aerosolized drugs in the human respiratory tract due to hygroscopic growth. J Aerosol Med1989;2:271–284.
9.
MartonenTB, KatzI.Deposition patterns of polydisperse aerosols within human lungs. J Aerosol Med1993;6:251–274.
10.
MartonenTB. Mathematical model for the selective deposition of inhaled pharmaceuticals. J Pharm Sci1993;82(12):1191–1199.
11.
KimCS, KangTC. Comparative measurement of lung deposition of inhaled fine particles in normal subjects and patients with obstructive airway disease. Am J Respir Crit Care Med1997;155(3):899–905.
12.
AndersonPJ, BlanchardJD, BrainJD, FeldmanHA, McNamaraJJ, HeyderJ.Effect of cystic fibrosis on inhaled aerosol boluses. Am Rev Respir Dis1989;140(5):1317–1324.
13.
O'RiordanTG, WalserL, SmaldoneGC. Changing patterns of aerosol deposition during methacholine bronchoprovocation. Chest1993;103(5):1385–1389.
14.
IlowiteJS, GorvoyJD, SmaldoneGC. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis1987;136(6):1445–1449.
15.
AndersonPJ, WilsonJD, HillerFC. Respiratory tract deposition of ultrafine particles in subjects with obstructive or restrictive lung disease. Chest1990;97(5):1115–1120.
16.
KimCS, BrownLK, LewarsGG, SacknerMA. Deposition of aerosol particles and flow resistance in mathematical and experimental airway models. J Appl Physiol1983;55(1 Pt 1):154–163.
17.
GondaI.Targeting by deposition. In: HickeyAJ, editor. Pharmaceutical aerosol inhalation technology. New York: Marcel Decker; 1992: 61–82.
18.
KimCS, EldridgeMA, SacknerMA. Oropharyngeal deposition and delivery aspects of metered-dose inhaler aerosols. Am Rev Respir Dis1987;135(1):157–164.
19.
SmithEC, DenyerJ, KendrickAH. Comparison of twenty three nebulizer/compressor combinations for domiciliary use. Eur Respir J1995;8(7):1214–1221.
20.
AlvineGF, RodgersP, FitzsimmonsKM, AhrensRC. Disposable jet nebulizers: how reliable are they?Chest1992;101(2):316–319.
21.
WilsonAF, MukaiDS, AhdoutJJ. Effect of canister temperature on performance of metered-dose inhalers. Am Rev Respir Dis1991;143(5 Pt 1):1034–1037.
22.
CoatesAL, MacNeishCF, MeisnerD, KelemenS, ThibertR, MacDonaldJ, VadasE.The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols. Chest1997;111(5):1206–1212.
23.
DennisJH, HendrickDJ. Design characteristics for drug nebulizers. J Med Eng Technol1992;16(2):63–68.
24.
O'DohertyMJ, MillerRF. Aerosols for therapy and diagnosis (review). Eur J Nucl Med1993;20(12):1201–1213.
25.
ClarkAR, GondaI, NewhouseMT. Towards meaningful laboratory tests for evaluation of pharmaceutical aerosols. J Aerosol Med1998;11Suppl 1:S1–S7.
26.
DennisJH. A review of issues relating to nebulizer standards. J Aerosol Med1998;11Suppl 1:S73–79.
27.
AdamsWP, PoochikianG, TaylorAS, PatelRM, BurkeGP, WilliamsRL. Regulatory aspects of modifications to innovator bronchodilator metered dose inhalers and development of generic substitutes (review). J Aerosol Med1994;7(2):119–134.
28.
Van OortM.In vitro testing of dry powder inhalers. Aerosol Sci Technol1995;22:364–373.
29.
US Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research. Guidance for industry: metered dose inhaler (MDI) and dry powder inhaler (DPI) drug products (Draft). Oct, 1998.
30.
LaubeBL, JashnaniR, DalbyRN. Predicting in vivo lung deposition of cromolyn sodium from in vitro estimates. J Aerosol Med1998;11Suppl 1:S35–S42.
31.
NewmanSP. How well do in vitro particle size measurements predict drug delivery in vivo?J Aerosol Med1998;11Suppl 1:S97–S104.
32.
OlssonB, AskingL, BorgströmL, BondessonE.Effect of inlet throat on the correlation between measured fine particle dose and lung deposition. In: DalbyRN, ByronPR, FarrSY, editors. Respiratory drug delivery V. Buffalo Grove IL: Interpharm Press; 1996: 273–281.
33.
VelasquesDJ, GabrioB.Metered dose inhaler aerosol deposition in a model of the human respiratory system and a comparison with clinical deposition studies. J Aerosol Med1998;11Suppl 1:S23–S28.
34.
LeachCL. Relevance of radiolabeled steroid inhalation studies to clinical outcomes. J Aerosol Med1998;11Suppl 1:S29–S34.
35.
SmaldoneGC, FuhrerJ, SteigbigelRT, McPeckM.Factors determining pulmonary deposition of aerosolized pentamidine in patients with human immunodeficiency virus infection. Am Rev Respir Dis1991;143(4 Pt 1):727–737.
36.
RauJL, ZhuY.Reservoir design and dose availability with long-term metered dose inhaler corticosteroid use. J Aerosol Med1998;11(1):15–26.
37.
McPeckM, TandonR, HughesK, SmaldoneGC. Aerosol delivery during continuous nebulization. Chest1997;111(5):1200–1205.
38.
BarryPW, O'CallaghanC.Drug output from nebulizers is dependent on the method of measurement. Eur Respir J1998;12(2):463–466.
39.
O'RiordanTG, WeinsteinMD, MaoY.Bench testing of nebulizers: a comparison of three methods. J Aerosol Med1999;12(2):59–66.
40.
AventML, GalP, RansomJL, BrownYL, HansenCJ, RickettsWA, SozaF.Evaluating the delivery of nebulized and metered-dose inhalers in an in vitro infant ventilator lung model. Ann Pharmacother1999;33(2):144–148.
41.
O'DohertyMJ, ThomasSHL, PageCJ, TreacherDF, NunanTO. Delivery of a nebulized aerosol to a lung model during mechanical ventilation: effect of ventilator settings and nebulizer type, position, and volume of fill. Am Rev Respir Dis1992;146(2):383–388.
42.
FuchsHJ, BorowitzDS, ChristiansenDH, MorrisEM, NashML, RamseyBW, et al.Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med1994;331(10):637–642.
43.
RamseyBW, PepeMS, QuanJM, OttoKL, MontgomeryAB, Williams-WarrenJ, et al.Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med1999;340(1):23–30.
44.
NewmanSP. Scintigraphic assessment of therapeutic aerosols (review). Crit Rev Ther Drug Carrier Syst1993;10(1):65–109.
45.
GondaI.Scintigraphic techniques for measuring in vivo deposition. J Aerosol Med1996;9Suppl 1:S59–S67.
46.
ChanHK. Use of single photon emission computed tomography in aerosol studies (review). J Aerosol Med1993;6(1):23–36.
47.
PhippsPR, GondaI, BaileyDL, BorhamP, BautovichG, AndersonSD. Comparisons of planar and tomographic gamma scintigraphy to measure the penetration index of inhaled aerosols. Am Rev Respir Dis1989;139(6):1516–1523.
48.
PerringS, SummersQ, FlemingJS, NassimMA, HolgateST. A new method of quantification of the pulmonary regional distribution of aerosols using combined CT and SPECT and its application to nedocromil sodium administered by metered dose inhaler. Br J Radiol1994;67(793):46–53.
49.
ZainudinBMZ, BiddiscombeM, TolfreeSEJ, ShortM, SpiroSG. Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution. Thorax1990;45(6):469–473.
50.
DolovichM.The relevance of aerosol particle size to clinical response. J Biopharm Sci1992;3:139–145.
51.
HultquistC, WollmerP, EklundhG, JonsonB.Effect of inhaled terbutaline sulphate in relation to its deposition in the lungs. Pulm Pharmac1992;5(2):127–132.
52.
NewmanSP, WeiszAWB, TalaeeN, ClarkeSW. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax1991;46(10):712–716.
53.
SimondsAK, NewmanSP, JohnsonMA, TalaeeN, LeeCA, ClarkeSW. Alveolar targeting of aerosol pentamidine: toward a rational delivery system. Am Rev Respir Dis1990;141(1):827–829.
54.
SmaldoneGC, DickinsonG, MarcialE, YoungE, SeymourJ.Deposition of aerosolized pentamidine and failure of pneumocystis prophylaxis. Chest1992;101(1):82–87.
55.
SmaldoneGC. Deposition patterns of nebulized drugs: is the pattern important?J Aerosol Med1994;7Suppl 1:S25–S32.
56.
WigleyFM, LondonoJH, WoodSH, ShippJC, WaldmanRH. Insulin across respiratory mucosae by aerosol delivery. Diabetes1971;20(8):552–556.
57.
LaubeBL, GeorgopoulosA, AdamsGK3rd. Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic patients. JAMA1993;269(16):2106–2109.
58.
LaubeBL, BenedictGW, DobsAS. Time to peak insulin level, relative bioavailability, and effect of site of deposition of nebulized insulin in patients with noninsulin-dependent diabetes mellitus. J Aerosol Med1998;11(3):153–173.
59.
HochhausG, MöllmannH.Pharmacokinetic/pharmacodynamic characteristics of the B-2-agonists terbutaline, salbutamol and fenoterol (review). Int J Clin Pharmacol Ther Toxicol1992;30(9):342–362.
60.
NewnhamDM, LipworthBJ. Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system ("Ventstream"). Thorax1994;49(8):762–770.
61.
NewmanSP, ClarkeSW. Bronchodilator delivery from Gentlehaler, a new low-velocity pressurized aerosol inhaler. Chest1993;103(5):1442–1446.
62.
NewnhamDM, McDevittDG, LipworthBJ. Comparison of the extrapulmonary B2-adrenoceptor responses and pharmacokinetics of salbutamol given by standard metered dose-inhaler and modified actuator device. Br J Clin Pharmacol1993;36:445–450.
63.
ClarkDJ, Gordon-SmithJ, McPhateG, ClarkG, LipworthBJ. Lung bioavailability of generic and innovator salbutamol metered dose inhalers. Thorax1996;51(3):325–326.
64.
LipworthBJ, ClarkDJ. Early lung absorption profile of non-CFC salbutamol via small and large volume plastic spacer devices. Br J Clin Pharmacol1998;46(1):45–48.
65.
LipworthBJ, ClarkDJ. Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices. Pulm Pharmacol Ther1997;10(4):211–214.
66.
LipworthBJ, ClarkDJ. Effects of airway calibre on lung delivery of nebulised salbutamol. Thorax1997;52(12):1036–1039.
67.
AndersonPJ, ZhouX, BreenP, GannL, LogsdonTW, CompadreCM, HillerFC. Pharmacokinetics of (R, S)-albuterol after aerosol inhalation in healthy adult volunteers. J Pharm Sci1998;87(7):841–844.
68.
BorgströmL, DeromE, StahlE, Wahlin-BollE, PauwelsR.The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med1996;153(5):1636–1640.
69.
BorgströmL, NewmanS, WeiszA, MorénF.Pulmonary deposition of inhaled terbutaline: comparison of scanning gamma camera and urinary excretion methods. J Pharm Sci1992;81(8):753–755.
70.
HindleM, ChrystynH.Determination of the relative bioavailability of salbutamol to the lung following inhalation. Br J Clin Pharmacol1992;34(4):311–315.
71.
HindleM, NewtonDA, ChrystynH.Dry powder inhalers are bioequivalent to metered-dose inhalers: a study using a new urinary albuterol (salbutamol) assay technique. Chest1995;107(3):629–633.
72.
HindleM, ChrystynH.Relative bioavailabiliy of salbutamol to the lung following inhalation using metered dose inhalation methods and space devices. Thorax1994;49(6):549–553.
73.
HindleM, NewtonDAG, ChrystynH.Investigations of an optimal inhaler technique with the use of urinary salbutamol excretion as a measure of relative bioavailability to the lung. Thorax1993;48(6):607–610.
74.
ClarkDJ, TanKS, LipworthBJ. Evaluation of plasma and urinary salbutamol levels in COPD. Eur J Clin Pharmacol1996;51(1):91–93.
75.
ClarkDJ, LipworthBJ. Dose-response of inhaled drugs in asthma: an update (review). Clin Pharmacokinet1997;32(1):58–74.
76.
PedersenS, SteffensenG, OhlssonSV. The influence of orally deposited budesonide on the systemic availability of budesonide after inhalation from a Turbuhaler. Br J Clin Pharmacol1993;36(3):211–214.
77.
SealeJP, HarrisonLI. Effect of changing the fine particle mass of inhaled beclomethasone dipropionate on intrapulmonary deposition and pharmacokinetics (review). Respir Med1998;92Suppl A:9–15.
78.
HarrisonLI, ColiceGL, DonnellD, SoriaI, DockhornR.Adrenal effects and pharmacokinetics of CFC-free beclomethasone dipropionate: a 14-day dose-response study. J Pharm Pharmacol1999;51(3):263–269.
79.
RiegelmanRK. Studying a study and testing a test. Boston: Little, Brown; 1981: 21–27.
80.
MargolisML. PFT principles and bronchodilator testing in clinical practice: a guide for primary care physicians. Compr Ther1998;24(9):441–445.
81.
American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis1991;144(5):1202–1218.
82.
DompelingE, van SchayckCP, MolemaJ, AkkermansR, FolgeringH, van GrunsvenPM, van WeelC.A comparison of six different ways of expressing the bronchodilating response in asthma and COPD; reproducibility and dependence of prebronchodilator FEV. Eur Respir J1992;5(8):975–981.
83.
EliassonO, DegraffACJr. The use of criteria for reversibility and obstruction to define patient groups for bronchodilator trials. Am Rev Respir Dis1985;132(4):858–864.
84.
TweeddalePM, AlexanderF, McHardyGJR. Short term variability in FEV, and bronchodilator responsiveness in patients with obstructive ventilatory defects. Thorax1987;42(7):487–490.
85.
GuyattGH, TownsendM, NogradiS, PugsleySO, KellerJL, NewhouseMT. Acute response to bronchodilator: an imperfect guide for bronchodilator therapy in chronic airflow limitation. Arch Intern Med1988;148(9):1949–1952.
86.
CazzolaM, VinciguerraA, Di PernaF, MateraMG. Early reversibility to salbutamol does not always predict bronchodilation after salmeterol in stable chronic obstructive pulmonary disease. Respir Med1998;92(8):1012–1016.
87.
SmithHR, IrvinCG, CherniackRM. The utility of spirometry in the diagnosis of reversible airways obstruction. Chest1992;101(6):1577–1581.
88.
PellegrinoR, RodarteJR, BrusascoV.Assessing the reversibility of airway obstruction. Chest1998;114(6):1607–1612.
89.
NewhouseMT, DolovichMB, KazinF.Dose-effect relationship of the B-agonists fenoterol and salbutamol in patients with asthma. Chest1994;105(6):1738–1742.
90.
MellenA, ArvidssonP, PalmqvistM, LotvallJ.Equivalent bronchodilation with salbutamol given via pMDI or Turbuhaler. Am J Respir Crit Care Med1999;159(5 Pt 1):1663–1665.
91.
HaahtelaT, VidgrenM, NybergA, KorhonenP, LaurikainenK, SilvastiM.A novel multiple dose powder inhaler: salbutamol powder and aerosol give equal bronchodilatation with equal doses. Ann Allergy1994;72(2):178–180.
92.
GrossNJ, PettyTL, FriedmanM, SkorodinMS, SilversGW, DonohueJF. Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease: a three-center study. Am Rev Respir Dis1989;139(5):1188–1191.
93.
MestitzH, CoplandJM, McDonaldCF. Comparison of outpatient nebulized vs metered dose inhaler terbutaline in chronic airflow obstruction. Chest1989;96(6):1237–1240.
94.
ChapmanKR, FribergK, BalterMS, HylandRH, AlexanderM, AbboudRT, et al.Albuterol via Turbuhaler versus albuterol via pressurized metered-dose inhaler in asthma. Ann Allergy Asthma Immunol1997;78(1):59–63.
95.
HansenEF, PhanarethK, LaursenLC, Kok-JensenA, DirksenA.Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med1999;159(4 Pt 1):1267–1271.
96.
TurnerMO, PatelA, GinsburgS, FitzGeraldJM. Bronchodilator delivery in acute airflow obstruction: a meta-analysis. Arch Intern Med1997;157(15):1736–1744.
97.
National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma. Expert Panel Report 2. 1997: 31–32.
98.
SlyPD, CahillP, WilletK, BurtonP.Accuracy of mini peak flow meters in indicating changes in lung function in children with asthma. BMJ1994;308(6928):572–574.
99.
ReddelHK, WareSI, SalomeCM, MarksGB, JenkinsCR, WoolcockAJ. Standardization of ambulatory peak flow monitoring: the importance of recent B2-agonist inhalation. Eur Respir J1998;12(2):309–314.
100.
BrandPLP, DuivermanEJ, WaalkensHJ, van Essen-ZandvlietEEM, KerrebijnKF. Peak flow variation in childhood asthma: correlation with symptoms, airways obstruction, and hyperresponsiveness during long-term treatment with inhaled corticosteroids. Dutch CNSLD Study Group. Thorax1999;54(2):103–107.
101.
TattersfieldAE, PostmaDS, BarnesPJ, SvenssonK, BauerCA, O'ByrnePM, et al.Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med1999;160(2):594–599.
102.
VerberneAAPH, FullerR.An overview of nine clinical trials of salmeterol in an asthmatic population. Respir Med1998;92(5):777–782.
103.
CockcroftDW, SwystunVA. Effect of single doses of S-salbutamol, R-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine. Thorax1997;52(10):845–848.
104.
JuniperEF, KlinePA, VanzieleghemMA, RamsdaleEH, O'ByrnePM, HargreaveFE. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis1990;142(4):832–836.
105.
BlakeKV, HoppeM, HarmanE, HendelesL.Relative amount of albuterol delivered to lung receptors from a metered-dose inhaler and nebulizer solution: bioassay by histamine bronchoprovocation. Chest1992;101(2):309–315.
106.
DoumaWR, de GooijerA, RijckenB, SchoutenJP, KoëterGH, WeissST, PostmaDS. Lack of correlation between bronchoconstrictor response and bronchodilator response in a population-based study. Eur Respir J1997;10(12):2772–2777.
107.
SontJK, WillemsLNA, BelEH, van KriekenHJM, VandenbrouckeJP, SterkP.Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med1999;159(4 Pt 1):1043–1051.
108.
HaleyKJ, DrazenJM. Inflammation and airway function in asthma: what you see is not necessarily what you get (review). Am J Respir Crit Care Med1998;157(1):1–3.
109.
CrimiE, SpanevelloA, NeriM, IndPW, RossiGA, BrusascoV.Dissociation between airway inflammation and airway hyperresponsiveness in allergic asthma. Am J Respir Crit Care Med1998;157(1):4–9.
110.
BentleyAM, MenzG, StorzC, RobinsonDS, BradleyB, JefferyPK, DurhamSR, KayAB. Identification of T lymphocytes, macrophages, and activated eosinophils in the bronchial mucosa in intrinsic asthma: relationship to symptoms and bronchial responsiveness. Am Rev Respir Dis1992;146(2):500–506.
111.
KirbyJG, HargreaveFE, GleichGJ, O'ByrnePM. Bronchoalveolar cell profiles of asthmatic and nonasthmatic subjects. Am Rev Respir Dis1987;136(2):379–383.
112.
JatakanonA, KharitonovS, LimS, BarnesPJ. Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma. Thorax1999;54(2):108–114.
113.
LimS, JatakanonA, JohnM, GilbeyT, O'ConnorBJ, ChungKF, BarnesPJ. Effect of inhaled budesonide on lung function and airway inflammation: assessment by various inflammatory markers in mild asthma. Am J Respir Crit Care Med1999;159(1):22–30.
114.
CatesCJ. Comparison of holding chambers and nebulisers for beta-agonists in acute asthma. The Cochrane Database of Systematic Reviews. The Cochrane Collaboration; Issue 3. Oxford: Update Software: 1996.
115.
CarmichaelJ, DuncanD, CromptonGK. Beclomethasone dipropionate dry-powder inhalation compared with conventional aerosol in chronic asthma. Br Med J1978;2(6138):657–658.
116.
BronskyE, BucholtzGA, BusseWW, ChervinskyP, CondemiJ, GhafouriMA, et al.Comparison of inhaled albuterol powder and aerosol in asthma. J Allergy Clin Immunol1987;79(5):741–747.
117.
AgertoftL, PedersenS.A randomized, double-blind dose reduction study to compare the minimal effective dose of budesonide Turbuhaler and fluticasone propionate Diskhaler. J Allergy Clin Immunol1997;99(6 Pt 1):773–780.
118.
BorgGAV. Psychophysical bases of perceived exertion. Med Sci Sports Exerc1982;14(5):377–381.
119.
WolkoveN, DajczmanE, ColaconeA, KreismanH.The relationship between pulmonary function and dyspnea in obstructive lung disease. Chest1989;96(6):1247–1251.
120.
MoyML, LantinML, HarverA, SchwartzsteinRM. Language of dyspnea in assessment of patients with acute asthma treated with nebulized albuterol. Am J Respir Crit Care Med1998;158(3):749–753.
121.
ApterAJ, AffleckG, ReisineST, TennenHA, BarrowsE, WellsM, et al.Perception of airway obstruction in asthma: sequential daily analyses of symptoms, peak expiratory flow rate, and mood. J Allergy Clin Immunol1997;99(5):605–612.
122.
BrandPL, RijckenB, SchoutenJP, KoëterGH, WeissST, PostmaDS. Perception of airway obstruction in a random population sample: relationship to airway hyperresponsiveness in the absence of respiratory symptoms. Am Rev Respir Dis1992;146(2):396–401.
123.
O'DonnellDE, LamM, WebbKA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med1999;160(2):542–549.
124.
JonesPW. Issues concerning health-related quality of life in COPD (review). Chest1995;107(5 Suppl):187S–193S.
125.
GuyattGH, BermanLB, TownsendM, PugsleySO, ChambersLW. A measure of quality of life for clinical trials in chronic lung disease. Thorax1987;42(10):773–778.
126.
JonesPW, QuirkFH, BaveystockCM, LittlejohnsP.A self-complete measure of health status for chronic airflow limitation. The St George's Respiratory Questionnaire. Am Rev Respir Dis1992;145(6):1321–1327.
127.
HylandME, FinnisS, IrvineSH. A scale for assessing quality of life in adult asthma sufferers. J Psychosom Res1991;35(1):99–110.
128.
JuniperEF, JohnstonPR, BorkhoffCM, GuyattGH, BouletLP, HaukiojaA.Quality of life in asthma clinical trials: comparison of salmeterol and salbutamol. Am J Respir Crit Care Med1995;151(1):66–70.
129.
LipworthBJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med1999;159(9):941–955.
130.
ClarkDJ, GroveA, CargillRI, LipworthBJ. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax1996;51(3):262–266.
